Cite
HARVARD Citation
Basu, B. et al. (2018). Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer. Annals of oncology. pp. 1918-1925. [Online].